Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 127

1.

Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid.

Hugenberg V, Behrends M, Wagner S, Hermann S, Schäfers M, Kolb HC, Szardenings K, Walsh JC, Gomez LF, Kopka K, Haufe G.

EJNMMI Radiopharm Chem. 2018 Jul 27;3:10. doi: 10.1186/s41181-018-0045-0. eCollection 2018 Dec.

2.

Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy.

Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller K, Amaral H, Weber W, Schwaiger M, Hohenfellner M, Kratochwil C, Debus J, Haberkorn U, Choyke P, Kramer V, Kopka K, Eiber M.

J Nucl Med. 2018 Jul 24. pii: jnumed.118.212233. doi: 10.2967/jnumed.118.212233. [Epub ahead of print]

PMID:
30042163
3.

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Jul 7. doi: 10.1007/s00259-018-4079-z. [Epub ahead of print]

PMID:
29980832
4.

68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.

Koerber SA, Will L, Kratochwil C, Haefner MF, Rathke H, Kremer C, Merkle J, Herfarth K, Kopka K, Choyke PL, Holland-Letz T, Haberkorn U, Debus J, Giesel FL.

J Nucl Med. 2018 Jul 5. pii: jnumed.118.211086. doi: 10.2967/jnumed.118.211086. [Epub ahead of print]

PMID:
29976697
5.

Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT.

Afshar-Oromieh A, Sattler LP, Steiger K, Holland-Letz T, da Cunha ML, Mier W, Neels O, Kopka K, Weichert W, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1179-1187. doi: 10.1007/s00259-018-3965-8. Epub 2018 Mar 1.

PMID:
29497802
6.

Monomeric and Dimeric 68Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPrs).

Liolios C, Buchmuller B, Bauder-Wüst U, Schäfer M, Leotta K, Haberkorn U, Eder M, Kopka K.

J Med Chem. 2018 Mar 8;61(5):2062-2074. doi: 10.1021/acs.jmedchem.7b01856. Epub 2018 Feb 22.

PMID:
29432691
7.

Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT.

Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, Neels OC, Cardinale J, Hadaschik B, Hohenfellner M, Kopka K, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Apr;59(4):632-635. doi: 10.2967/jnumed.117.196329. Epub 2018 Feb 1.

PMID:
29419475
8.

Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5 /P450 reductase null (HBRN) mice.

Reed L, Mrizova I, Barta F, Indra R, Moserova M, Kopka K, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM.

Arch Toxicol. 2018 Apr;92(4):1625-1638. doi: 10.1007/s00204-018-2162-7. Epub 2018 Jan 24.

9.

[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty.

Giesel FL, Will L, Paddubny K, Kremer C, Rathke H, Radtke JP, Kopka K, Haufe S, Haberkorn U, Kratochwil C.

Clin Genitourin Cancer. 2018 Apr;16(2):111-113. doi: 10.1016/j.clgc.2017.11.008. Epub 2017 Dec 6. No abstract available.

10.

Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.

Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, Neels O, Reyneke F, Haberkon U, Kopka K, Sathekge M.

J Nucl Med. 2018 Jul;59(7):1076-1080. doi: 10.2967/jnumed.117.204669. Epub 2017 Dec 21.

PMID:
29269569
11.

Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients.

Will L, Giesel FL, Freitag MT, Berger AK, Mier W, Kopka K, Koerber SA, Rathke H, Kremer C, Kratochwil C, Kauczor HU, Haberkorn U, Weber TF.

Cancer Imaging. 2017 Dec 20;17(1):30. doi: 10.1186/s40644-017-0132-6.

12.

PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.

Baranski AC, Schäfer M, Bauder-Wüst U, Roscher M, Schmidt J, Stenau E, Simpfendörfer T, Teber D, Maier-Hein L, Hadaschik B, Haberkorn U, Eder M, Kopka K.

J Nucl Med. 2018 Apr;59(4):639-645. doi: 10.2967/jnumed.117.201293. Epub 2017 Nov 30.

PMID:
29191856
13.

Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.

Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F.

Theranostics. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017.

14.

Reply: PSMA Ligands for Imaging Prostate Cancer: Alternative Labeling by Complex Formation with Al18F2.

Giesel FL, Kopka K.

J Nucl Med. 2017 Dec;58(12):2041. doi: 10.2967/jnumed.117.198176. Epub 2017 Nov 9. No abstract available.

PMID:
29123010
15.

Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas.

Glowa C, Peschke P, Brons S, Neels OC, Kopka K, Debus J, Karger CP.

Radiat Oncol. 2017 Nov 9;12(1):174. doi: 10.1186/s13014-017-0914-9.

16.

Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy.

Paddubny K, Freitag MT, Kratochwil C, Koerber S, Radtke JP, Sakovich R, Kopka K, Giesel FL.

Clin Genitourin Cancer. 2018 Apr;16(2):103-105. doi: 10.1016/j.clgc.2017.09.014. Epub 2017 Oct 5. No abstract available.

17.

Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[a]pyrene in prokaryotic and eukaryotic expression systems.

Stiborová M, Indra R, Moserová M, Bořek-Dohalská L, Hodek P, Frei E, Kopka K, Schmeiser HH, Arlt VM.

Monatsh Chem. 2017;148(11):1959-1969. doi: 10.1007/s00706-017-2002-0. Epub 2017 Jul 10.

18.

Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPIRINHA-accelerated MR-based attenuation correction.

Freitag MT, Fenchel M, Bäumer P, Heußer T, Rank CM, Kachelrieß M, Paech D, Kopka K, Bickelhaupt S, Dimitrakopoulou-Strauss A, Maier-Hein K, Floca R, Ladd ME, Schlemmer HP, Maier F.

Eur J Radiol. 2017 Nov;96:12-20. doi: 10.1016/j.ejrad.2017.09.007. Epub 2017 Sep 13.

PMID:
29103469
19.

Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study.

Freitag MT, Kesch C, Cardinale J, Flechsig P, Floca R, Eiber M, Bonekamp D, Radtke JP, Kratochwil C, Kopka K, Hohenfellner M, Stenzinger A, Schlemmer HP, Haberkorn U, Giesel F.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):340-347. doi: 10.1007/s00259-017-3854-6. Epub 2017 Oct 16.

PMID:
29038888
20.

Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer.

Cardinale J, Martin R, Remde Y, Schäfer M, Hienzsch A, Hübner S, Zerges AM, Marx H, Hesse R, Weber K, Smits R, Hoepping A, Müller M, Neels OC, Kopka K.

Pharmaceuticals (Basel). 2017 Sep 27;10(4). pii: E77. doi: 10.3390/ph10040077.

Supplemental Content

Loading ...
Support Center